psoriatic%20arthritis
PSORIATIC ARTHRITIS
Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.

Psoriatic Arthritis References

  1. Gossec L, Smolen JS, Gaujoux-Viala C, et al; European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. PMID: 21953336
  2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermat. 2008 May;58(5):851-864. doi: 10.1016/j.jaad.2008.02.040. PMID: 18423261
  3. Kyle S, Chandler D, Griffiths M, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology. 2005 Mar;44(3):390-397. PMID: 15695305
  4. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9):1387-1394. doi: 10.1136/ard.2008.094946. PMID: 18952643
  5. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78. PMID: 4581554
  6. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-2673. PMID: 16871531
  7. Voorhees AV, Feldman SR, Koo JYM, et al. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. The National Psoriasis Foundation; 2009
  8. MedWormhttp://www.medworm.com/rss/index.php/Allergy-%26-Immunology/3/http://www.medworm.com/rss/medicalfeeds/specialities/Allergy-Immunology.xml
  9. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  10. Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. SIGN. http://www.sign.ac.uk. 2010. Accessed 17 Jul 2011
  11. National Institute for Health and Care Excellence. Golimumab for the treatment of psoriatic arthritis. NICE. http://www.nice.org.uk/. 2011
  12. Coates L, Tillett W, Chandler P, et al. The 2012 British Society for Rheumatology guidelines for the treatment of psoriatic arthritis with biologicals. http://www.rheumatology.org.uk/includes/documents/cm_docs/2012/b/bsr_guidelines_2012_treatment_of_psoriatic_arthritis_with_biologics.pdf. 2012. Accessed 24 Jul 2013
  13. National Institute for Health and Care Excellence. Review of TA199; Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (includes a review of NICE technology appraisal guidance 104 and 125), and TA220; Golimumab for the treatment of psoriatic arthritis. NICE. http://www.nice.org.uk/. 2013
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).